VeriSIM partners with Clarivate for early-stage drug development
VeriSIM Life, a developer of AI tools for drug development, partnered with Clarivate, an information services company, to provide pharma and biotech companies with R&D insights through their solutions.
According to the companies, they will offer tools that are able to de-risk and accelerate drug discovery, as well as helping to avoid late-stage failures during clinical trials. The two solutions that will be combined are VeriSIM’s BIOiSIM platform, and Clarivate’s Cortellis Drug Discovery Intelligence.
Clarivate’s tool provides preclinical drug intelligence, which involves access to a research database that has been manually curated, validated, and shared by scientists.
Access to the database delivers companies data on pipelines, patents, literature, and conferences. In addition, it can be used to identify, validate and prioritize targets and biomarkers, as well as giving information on metabolic pathways and potential toxicity events.
VeriSIM describes its own platform as a ‘virtual drug development engine’ that uses AI and machine learning to make early predictions about compound safety and efficacy. The solution also features a ‘Translational Index’ technology that is used to determine whether the strongest drug candidate to progress from a selection of options.
The company also offers to partner with organizations to co-develop new drugs using the platform to determine the most likely drug candidate to succeed, with VeriSIM noting that this can shorten development time.
Gavin Coney, VP of partnerships at Clarivate, said, “Working with the combination of Clarivate and VeriSIM Life will allow companies to benefit by gaining additional and valuable insights that can reduce risk, provide them with information to make more informed decisions with extraordinary accuracy, and bridge the translational gap between pre-clinical and clinical research. Ultimately, this partnership can bring life-saving treatments to patients more quickly.”
VeriSIM also owns a pharmaceutical subsidiary in the form of PulsoSIM Therapeutics. This company has been set up to target pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), using BIOiSIM to deliver its preclinical pipeline.
PulsoSIM has two assets in its pipeline, one for each of the mentioned conditions. PT001, which is currently in late preclinical studies for PAH, and PT002 for IPF, which is going through in-vitro studies.
The company was launched in 2021, and shortly after in June 2021, PT001 was granted orphan drug designation by the US Food and Drug Administration.
